Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions
Open Access
- 25 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1018202
Abstract
Opportunistic fungal infections have high mortality in patients with severe immune dysfunction. Growing evidence suggests that the immune environment of invasive fungal infections and cancers share common features of immune cell exhaustion through activation of immune checkpoint pathways. This observation gave rise to several preclinical studies and clinical case reports describing blockade of the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte Antigen 4 immune checkpoint pathways as an adjunct immune enhancement strategy to treat opportunistic fungal infections. The first part of this review summarizes the emerging evidence for contributions of checkpoint pathways to the immunopathology of fungal sepsis, opportunistic mold infections, and dimorphic fungal infections. We then review the potential merits of immune checkpoint inhibitors (ICIs) as an antifungal immunotherapy, including the incomplete knowledge of the mechanisms involved in both immuno-protective effects and toxicities. In the second part of this review, we discuss the limitations of the current evidence and the many unknowns about ICIs as an antifungal immune enhancement strategy. Based on these gaps of knowledge and lessons learned from cancer immunology studies, we outline a research agenda to determine a “sweet spot” for ICIs in medical mycology. We specifically discuss the importance of more nuanced animal models, the need to study ICI-based combination therapy, potential ICI resistance, the role of the immune microenvironment, and the impact of ICIs given as part of oncological therapies on the natural immunity to various pathogenic fungi.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institute of Allergy and Infectious Diseases
- University of Texas MD Anderson Cancer Center
This publication has 133 references indexed in Scilit:
- Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsisCritical Care, 2013
- Immune reconstitution inflammatory syndrome: the trouble with immunity when you had noneNature Reviews Microbiology, 2012
- Dose-Dependent Effect of Anti-CTLA-4 on Survival in SepsisShock, 2011
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionProceedings of the National Academy of Sciences, 2010
- Long-term mortality and quality of life in sepsis: A systematic review*Critical Care Medicine, 2010
- Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolitesBlood, 2009
- Dynamic, Morphotype-Specific Candida albicans β-Glucan Exposure during Infection and Drug TreatmentPLOS Pathogens, 2008
- The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungusHistoplasma capsulatumProceedings of the National Academy of Sciences, 2008
- Pretreatment with Empty Liposomes Attenuates the Immunopathology of Invasive Pulmonary Aspergillosis in Corticosteroid-Immunosuppressed MiceAntimicrobial Agents and Chemotherapy, 2007
- CTLA-4 Down-Regulates the Protective Anticryptococcal Cell-Mediated Immune ResponseInfection and Immunity, 2000